Entrada raises $116M to take DMD therapy into the clinic

Entrada Therapeutics has raised $116 million to develop intracellular biologics. The series B round will enable Entrada to start clinical development of a pipeline featuring treatments for diseases such as Duchenne muscular dystrophy (DMD).